UNITED STATES
SECURITIES EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM NT-10Q
BIOENVISION INC.
NOTIFICATION OF LATE FILING OF FORM 10-Q
For the Period Ended: December 31, 1998
PART I. REGISTRANT INFORMATION
Full name of Registrant: Bioenvision, Inc.
Former name of Registrant: Ascot Group, Inc.
City Center Bellevue, Suite 730
500 108th Avenue, Bellevue, WA 98004
PART II. RULE 12b-25 (b) and (c)
If the subject report could not be filed without unreasonable
effort or expense, and the registrant seeks relief pursuant to
Rule 12b-25(b), the following should be completed. (Check box if
appropriate).
(a) The reasons described in reasonable detail in
Part III of this form could not be eliminated
without unreasonable effort or expense;
[x] (b) The subject annual report on Form 10-Q will be
filed on or before the 5th calendar day
following the prescribed due date; and
(c) The accountant's statement or other exhibit
required by Rule 12b-25(c) has been attached if
applicable.
PART III. NARRATIVE
State below in reasonable detail the reasons why Form 10-Q could
not be filed within the prescribed time period:
The Registrant recently acquired another entity,
Bioenvision, Inc., and is currently awaiting updated financials
as of the end of the reporting period, December 31, 1998, from
the Registrant's accountant.
PART IV. OTHER INFORMATION
(1) Name and telephone number of person to contact in regard
to this notification:
Peter Moulinos (212) 265-4600
(Name) (Area Code) (Telephone number)
(2) Have all other periodic reports required under Section 13
or 15(d) of the Securities Exchange Act of 1934 during
the preceding 12 months or for such shorter period that
the registrant was required to file such report(s) been
filed? If the answer is no, identify report(s).
[x] Yes [ ] No
(3) Is it anticipated that any significant change in results
of operations from the corresponding period for the last
fiscal year will be reflected by the earnings statements
to be included in the subject report or portion thereof?
[ ] Yes [x] No
If so: attach an explanation of the anticipated change,
both narratively and quantitatively, and, if appropriate,
state the reasons why a reasonable estimate of the
results cannot be made.
The Company has caused this notification to be signed on its
behalf by the undersigned thereunto duly authorized.
Date: February 11, 1999
Bioenvision, Inc.
--------------------
By: /s/
Title:
